BindingDB

The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.2M data for 1.4M Compounds and 11.4K Targets. Of those, 1.6M data for 745K Compounds and 4.7K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Donate Now

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

Advanced Search

14 articles for D Aharony

The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Azepines and piperidines with dual norepinephrine dopamine uptake inhibition and antidepressant activity.EBI
Astrazeneca
Design, synthesis, and SAR of tachykinin antagonists: modulation of balance in NK(1)/NK(2) receptor antagonist activity.EBI
Astrazeneca Pharmaceuticals
Discovery of novel, orally active dual NK1/NK2 antagonists.EBI
Astrazeneca Pharmaceuticals
 
Substituted 2,4-diaminoquinazolines and 2,4-diamino-8-alkylpurines as antagonists of the neurokinin-2 (NK2) receptorEBI
TBA
Application of fragment-based lead generation to the discovery of novel, cyclic amidine beta-secretase inhibitors with nanomolar potency, cellular activity, and high ligand efficiency.EBI
Astrazeneca Pharmaceuticals
Structural analysis and optimization of NK(1) receptor antagonists through modulation of atropisomer interconversion properties.EBI
Astrazeneca Pharmaceuticals
The discovery of non-basic atrial natriuretic peptide clearance receptor antagonists. Part 1.EBI
Astrazeneca Pharmaceuticals
4-Alkylpiperidines related to SR-48968: potent antagonists of the neurokinin-2 (NK2) receptor.EBI
Zeneca Pharmaceuticals
Synthesis, structure-activity relationships, and pharmacological evaluation of a series of fluorinated 3-benzyl-5-indolecarboxamides: identification of 4-[[5-[((2R)-2-methyl-4,4,4-trifluorobutyl)carbamoyl]-1-methyl indol- 3-yl]methyl]-3-methoxy-N-[(2-methylphenyl)sulfonyl]benzamide, a potent, orallEBI
Zeneca Pharmaceuticals Group
Substituted 3-(phenylmethyl)-1H-indole-5-carboxamides and 1-(phenylmethyl)indole-6-carboxamides as potent, selective, orally active antagonists of the peptidoleukotrienes.EBI
Ici Pharmaceuticals Group
Evolution of a series of peptidoleukotriene antagonists: synthesis and structure/activity relationships of 1,3,5-substituted indoles and indazoles.EBI
Ici Pharmaceuticals Group
Therapeutic uses of selected pyrrolopyrimidine compounds with anti-mer tyrosine kinase activityBDB
University of North Carolina at Chapel Hill
Sulfoximine substituted quinazolines for pharmaceutical compositionsBDB
Evotec Internatonal
Synthesis and evaluation of novel inhibitors of Pim-1 and Pim-2 protein kinases.BDB
Medical University of South Carolina